the vaccine – Page 22 – Communicable Diseases Research

Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases

Review article

Published on 2022-06-012022-10-05
Journal: Thrombosis research [Category] COVID19(2023년), SARS, 변종,

Impact of vaccine hesitancy on secondary COVID-19 outbreaks in the US: an age-structured SIR model

미국의 2차 COVID-19 발병에 대한 백신 주저의 영향: 연령 구조화된 SIR 모델

Article

Published on 2022-06-012022-09-11
Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 변종,

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro

다양한 용도 변경 약물과 결합된 몰누피라비르는 시험관 내 인간 비강 상피에서 SARS-CoV-2 감염을 추가로 억제합니다

Article

Published on 2022-06-012022-09-11
Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제,

[키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Air-liquid interface antiviral activity Antiviral treatment antiviral treatments antivirals caused cellular Clinical efficacy clinical testing clinically Combination combinations complex Compound Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 drug drug combination drug combinations Drug repurposing effective effective antiviral treatment effort Emergency use evaluated highlighting identify Immunity in vitro in vitro model inhibit inhibiting molnupiravir nasal epithelium Potential treatment Repurposed drug SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication selected severe acute respiratory syndrome Coronavirus short duration tested the vaccine These data Treatment Vaccine variant worldwide pandemic
[DOI] 10.1016/j.biopha.2022.113058 PMC 바로가기 [Article Type] Article

Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine

Sinopharm/BBIBP-CorV 백신에 대한 면역 반응의 지속성

Article

Published on 2022-06-012022-09-11
Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] ACE2 age all age groups angiotensin Angiotensin-converting enzyme antibody Antibody Response Antibody responses assays blocking antibodies Cell Cohort COVID-19 declined detectable determine Efficacy ELISPOT ELISpot assays enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Ex vivo group groups Hospitalization immune response immune responses Immunity individual individuals interferon gamma investigated Kinetics long term memory B memory B cell overlapping peptide peptides persistence Protein RBD receptor Receptor-binding domain remained response SARS-CoV-2 second dose severe disease Sinopharm Sinopharm/BBIBP-CorV Spike protein T cell T cell response T cell responses the RBD the receptor-binding domain the spike protein the vaccine total antibodies total antibody Vaccine Vaccines variants variants of concern virus were assessed were measured
[DOI] 10.1002/iid3.621 PMC 바로가기 [Article Type] Article

Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases

리툭시맙은 자가면역 질환에서 COVID-19 백신에 대한 B 세포 반응을 손상시키지만 T 세포 반응을 손상시키지 않습니다

Article

Published on 2022-06-012022-09-12
Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] absence activated anti-spike antibody response anti-Spike IgG Antibody Response Autoimmune disease autoimmune disease patient BNT162b2 CD4 CD8 CD8 T cell cellular response control group COVID-19 COVID-19 vaccine cytokine dose flow cytometry functional healthy control healthy controls humoral Immunosuppressant immunosuppressants interferon-γ Messenger RNA mRNA Necrosis Neutralization assay neutralizing antibody not different Patient patients patients treated performed Pfizer-BioNTech proportion Responder response rituximab RTX SARS-CoV-2 peptide SARS-CoV-2 spike peptide shown staining T cell response the healthy the vaccine time treated vaccine dose
[DOI] 10.1002/art.42058 PMC 바로가기 [Article Type] Article

Clinical Characteristics of Patients with Acute Ischemic Stroke Previously Vaccinated Against COVID-19

Observational Study

Published on 2022-06-012022-10-05
Journal: Journal of stroke and cerebrovascular diseases : t [Category] 임상,

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies

림프성 악성종양 환자에서 BNT162b2 mRNA 백신 2회 및 3회 투여 후 항-SARS-CoV-2 항체 반응

Article

Published on 2022-06-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] affected anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD38 anti-RBD Anti-RBD IgG antibody antibody concentration Antibody concentrations Antibody Response B-cell malignancies B-cell malignancy benefit binding domain booster Cell Cohort Concentration conducted Course COVID-19 COVID-19 patient COVID-19 patients disorders dose effective evaluate haematological malignancies haematological malignancy Haematologicalmalignancies humoral Humoral response humoral responses IgG Immunocompromised increment IQR lymphoid lymphomas malignancies malignancy median monoclonal Mortality mRNA vaccination mRNA vaccine of BNT162b2 Patient patients patients treated plasma Plasma cell Prophylaxis quantification RBD SARS-CoV-2 Seroconversion seroconversion rate seroconverted serological serological response serology significantly spike the disease the vaccine therapy third dose Vaccine vaccine dose
[DOI] 10.1016/j.cmi.2022.02.029 PMC 바로가기 [Article Type] Article

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study

Observational Study

Published on 2022-06-012022-10-04
Journal: The Lancet. Global health [Category] COVID19(2023년), SARS, 임상,

[키워드] 95% CI adjusted Administered Admission Antigen approach AZD1222 BNT162b2 booster booster dose Booster vaccine calculated Cohort Complete confounders CoronaVac country COVID-19 COVID-19 vaccine Cox model death dose doses Effectiveness eligible evaluated Evidence excluded hazard ratios Heterologous homologous homologous or heterologous hospitalisation ICU admission inactivated individual individuals initiative intensive care laboratory-confirmed outcome outcomes Oxford-AstraZeneca participant Pfizer-BioNTech Policy Program prospective cohort study provide Regression model RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccines Science severe disease Sinovac stratified study period Support survival symptomatic the vaccine vaccination vaccination schedule Vaccine vaccine dose
[DOI] 10.1016/S2214-109X(22)00112-7 PMC 바로가기 [Article Type] Observational Study

Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak

Short communication

Published on 2022-06-012022-10-05
Journal: Journal of microbiology, immunology, and infection [Category] 임상, 진단, 치료기술,

[키워드] clinically COVID-19 COVID-19 outbreak COVID-19 vaccination effective Effectiveness immunogenicity Intervention outbreak pandemic PLWH populations SARS-CoV-2 the vaccine vaccine effectiveness with HIV
[DOI] 10.1016/j.jmii.2022.04.006 [Article Type] Short communication

Modeling waning and boosting of COVID-19 in Canada with vaccination

예방 접종으로 캐나다의 COVID-19 감소 및 증가 모델링

Article

Published on 2022-06-012022-09-11
Journal: Epidemics [Category] COVID19(2023년), SARS, 변종,